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(four lessons); c) caring for me (three lessons); d) providing 
everyday care (five lessons); and e) dealing with changing be-
haviour (ten lessons). Each lesson presents information about 
a specific topic and provides engaging, interactive exercises re-
lated to this topic. The user is given instant feedback.
Since attrition is common in online programmes, tailoring 
components and duration of the lessons to the individual is im-
portant, the more so because caregivers often experience time 
constraints due to their caregiving role6. iSupport enables care-
givers to choose lessons that are appealing and most relevant 
to them.
iSupport has been developed as an online or web-based 
 self-help programme, but it can also be linked to a caregiver 
platform (for example a Facebook group), a coach or a face-to-
face support group. Contacts with other caregivers or a coach 
might have added value; however, the human resources that 
are needed to moderate or guide are not always available, in 
particular in less developed countries.
When countries want to implement iSupport, translation 
and adaptation of the programme is needed. We assume that 
iSupport can be useful in different cultural contexts for differ-
ent groups of caregivers, if appropriate adaptations to context 
and culture are made for ecological validity9. For example, for 
caregivers of people with dementia, generational differences 
within cultures should be examined.
The WHO provides a standardized guide for translation and 
adaptation (available upon request from whodementia@who.
int) to ensure that the local version of iSupport is accurate and 
in line with the generic version, but at the same time appropri-
ate for the local target group of family caregivers. The guide de-
scribes the process to translate and adapt the generic English 
version and the actual changes that might be (in)appropriate 
in the programme, such as specific words, names, and links to 
local Alzheimer’s organizations and care and support services.
In several countries, iSupport is currently being adapted and 
implemented, for example in India, China, Japan, Portugal, 
Brazil, Australia and the Netherlands. In a next step, the usabil-
ity and effectiveness of iSupport will be studied and will guide 
the further improvement of this global course. Upon request 
by some countries, a generic hardcopy manual of iSupport for 
adaptation and implementation to local contexts will become 
available shortly.
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Evocative gene-environment correlation between genetic risk for 
schizophrenia and bullying victimization
Bullying victimization (BV) is a risk factor for the develop-
ment of psychotic experiences and psychotic disorders1,2. We 
used data from TRAILS (TRacking Adolescents’ Individual Lives 
Survey), a longitudinal cohort study of Dutch pre-adolescents3, 
to study the relationship between polygenic risk score for 
schizophrenia (SCZ-PRS) and BV, and the possible role of BV 
in mediating the effect of genetic risk for schizophrenia on the 
development of psychotic symptoms later in life.
Three assessment waves of TRAILS – T1 (10-12.5 years old), 
T2 (12.4-14.6 years old) and T3 (14.8-18.3 years old) – were con-
sidered. We assessed IQ using the Wechsler Intelligence Scale 
for Children (WISC), administered at T1; BV through peer nomi-
nation scores at T1 and T2; social competence at T1 using the 
Revised Class Play (RCP); teacher-reported relational aggression 
by Likert scales at T2; and lifetime psychotic experiences using 
the Community Assessment of Psychic Experiences Scale at T3.
We imputed TRAILS genotypic data using Sanger Imputa-
tion Service (1000 Genomes Project Phase 3 reference GRCh37/
hg19). We excluded siblings and pupils on special education, 
checked genotype quality, derived genomic components to 
control for ancestry, and computed individual polygenic risk 
scores (PRS) for schizophrenia, attention-deficit/hyperactivity 
disorder, autism, bipolar disorder, major depression, and ob-
sessive-compulsive disorder, using standard procedures4. We 
focused on PRS-6 (including variants with association p-value 
<0.05), a measure of genetic risk yielding the highest prediction 
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accuracy for schizophrenia5. We divided the sample into PRS 
tertiles, reflecting low, medium and high risk.
We explored whether BV was uniformly distributed across 
genetic groups, and whether BV mediated the path from ge-
netic risk to psychotic experiences. For the former assessment, 
we computed an ANOVA using BV at T1 and T2 (separately) 
as dependent variables; PRS tertiles as factor; gender, WISC 
and five genomic ancestry components as nuisance covariates 
(bias corrected-accelerated bootstrap, 1000 runs). For the lat-
ter assessment, we computed mediation analyses using psy-
chotic experiences at T3 as dependent variable, BV at T1 and 
T2 (separately) as mediators, and the PRS as multi-categorical 
predictor (sequential contrast; same covariates as above plus 
victimization-psychosis time interval; mean-centering; boot-
strap with 5000 runs; Cribari-Neto correction).
To account for different BV reporters, we additionally com-
puted a mediation model using the rank product of peer nomi-
nation and relational aggression scores at T2. We tested other 
peer nomination scores and genetic risk for other disorders 
to assess specificity of the effects. We additionally explored 
whether the effect of the SCZ-PRS on BV was mediated by so-
cial competence assessed at T1.
Analyses at T1 returned no significant PRS effects (N=650, all 
p>0.05). ANOVA at T2 returned a significant PRS effect on BV 
(N=625, F2,611=3.4, p=0.033, partial η2=0.011; observed power = 
64%). High PRS individuals had greater peer nomination scores 
compared to medium PRS subjects (N=417, p=0.017) as well as 
to a merged sample of low/medium risk individuals (N=625, 
F1,613=6.3, p=0.012, partial η2=0.01, observed power = 71%). SCZ-
PRS was directly associated with BV at T2, without significant 
mediation by social competence at T1 (N=558, partially stan-
dardized effect = 0.011). T2 mediation analysis revealed a signifi-
cant indirect effect of genetic risk on psychotic experiences at T3 
(N=610, partially standardized effect = 0.031). Victims suffered 
more frequent psychotic experiences at T3 (N=610, p=0.018). 
These results suggest that BV partially mediated the effect of 
SCZ-PRS on the frequency of psychotic symptoms developed at T3.
When BV was assessed based on both peer and teacher re-
port at T2, the effect was even larger, despite the reduced sam-
ple size (N=390, p=0.002). Only genetic risk for schizophrenia, 
and not for other disorders, was associated with BV. Only BV 
peer nomination, not other peer nomination measures, was as-
sociated with later psychotic symptoms.
In summary, we found that 13-14-year-old adolescents with 
greater SCZ-PRS experienced more severe bullying than their 
peers with lower SCZ-PRS, and that BV partially mediated the ef-
fect of genetic risk on the development of later psychotic symp-
toms. A possible mechanism through which this mediation may 
occur is evocative gene-environment correlation, i.e., the genetic 
risk carrier evoking particular reactions of other individuals, such 
as bullying. The effect is small (1% of the variance), but it is in line 
with other reported effects, e.g., SCZ-PRS explains at most 1.2% 
of the variance in symptoms across patients with schizophrenia.
Our sample sizes are small for a behavioral genetics study, 
a limitation we attempted to address by cumulating risk vari-
ants into PRS tertiles. Peer nomination is just one way to assess 
BV and results may differ based on other reporters6,7. However, 
findings persisted when assessing BV based on peer/teacher 
reports. Importantly, we did not use self-reports, which may 
be influenced by paranoia. The prospective data collection re-
duced the risk of retrospective memory bias.
We studied risk for schizophrenia, but used psychotic epi-
sodes as a clinical proxy. Schizophrenia risk may overlap only 
partially with risk for psychosis, but risk variants for psycho-
sis are not known. To the extent that genetic risk translation 
into clinical symptoms is mediated by environmental risk8, our 
findings call for efforts to antagonize BV of vulnerable individ-
uals to support mental health prevention6,9.
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